Black Diamond Reports Phase 2 Results for BDTX-1535 in Lung Cancer, Targets FDA Approval Path
Black Diamond Reports Phase 2 Results for BDTX-1535 in Lung Cancer, Targets FDA Approval Path
黑色金剛石報告了BDTX-1535在肺癌中的二期結果，目標爲FDA批准路徑
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC).
黑鑽石醫療（NASDAQ:BDTX）是一家臨床階段的腫瘤學公司，正在開發針對癌症患者中的致癌突變家族的MasterKey療法。今日報告了初步2期數據，展示BDTX-1535在復發/難治表皮生長因子受體（EGFR）突變（EGFRm）非小細胞肺癌（NSCLC）患者中鼓舞人心的臨床反應和持久性。
"Patients often become resistant to osimertinib with the emergence of on-target resistance EGFR mutations," said Sergey Yurasov, M.D., Chief Medical Officer of Black Diamond Therapeutics. "Our preliminary Phase 2 data demonstrate the potential of BDTX-1535 to deliver durable responses for these patients."
「患者經常對奧西美替尼產生耐藥性，伴隨靶點抵抗性EGFR突變的出現，」黑鑽石醫療首席醫學官Sergey Yurasov博士表示。「我們初步的2期數據展示了BDTX-1535爲這些患者提供持久性反應的潛力。」
"Patients with...
「復...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間